THE STUDY
Authors need to make the reader aware of the study's limitations throughout the paper: e.g. mentioning candidate competing hypotheses to opioid exposure for CHD in the opiate-using population, accounting for the number of patients screened, included, and excluded for the study. It is unclear whether this was an open-ended (and thus weaker) design or with a predefined period of enrollment and End-of-study (date and/or number of observations). It would ease the readers' understanding of this study's importance and relevance if the Authors explained to the reader how arterial stiffness is consistent with more general CHD data from other (and preferably larger) OMT studies other than those conducted by the First Author; e. Table I is too long and most if not all of its contents should be incorporated into the text.
REPORTING & ETHICS
It is unclear whether patients received naltrexone treatment free of charge, and whether the written consent they gave were for full study participation or just for receiving naltrexone treatment.
As mentioned above, The Discussion and Conclusions sections, like the Title, should be edited to include more explicit mention of design limitations (see e.g. STROBE checklist item 20). While opioid agonists may contribute to arterial stiffness and/or increased aging, patients with motivation for abstinence from opioids through naltrexone implants may have introduced other significant lifestyle changes including diet, smoking, exercise, as well as changes in consumption of alcohol or non-opioid illicit drugs. This referee has not found a list of the confounding factors controlled for, despite this being stated in Discussion (pp 10) and checked on several items in the STROBE checklist; the checking of these STROBE items also appears inconsistent with authors briefly mentioning the lack of control over important confounding factors as a limitation (pp 12).
GENERAL COMMENTS
This is an interesting study on an important topic that would benefit from referencing other CHD-OMT studies (including more general ones) and also needs to reduce the risk of overstating its conclusions by drawing more attention to its limitations. -The reviewer completed the checklist but made no further comments.
VERSION 1 -AUTHOR RESPONSE
Response to Reviewers:
The reviewer requests that alternative candidate hypotheses be mentioned. A paragraph has been added to the tracked changes manuscript on page 11 which addresses this issue in detail.
The reviewer requests that a detailed description of how the sample size was arrived at be provided. A new paragraph addressing this issue specifically has been added after the limitation paragraph in the discussion, commencing on page 12.
The paper abstract now mentions the open study design under the design heading. This is expanded upon in the added paragraph just described.
Both studies from Oslo university mentioned by this reviewer have now been included. They are both mentioned on page 5 near the end of the Introduction. The Skeie paper is a retrospective study of 35 patients over about 6-7 years. Although various common causes of death and drug related complications are mentioned, formal death by system is not tabulated as is done in the definitive papers cited by Degenhardt and Khademi. The paper by Anchersen is mainly focused on QTc prolongation, but includes mortality figures. The Achersen results are consistent with those reported by many other workers. Comments to these effects are included at the relevant place in the Introduction.
Indeed the Khademi paper has over 50,000 enrolees, and the Degenhardt paper has over 46,000. Thus your reviewers err in fact to suggest that the present results have not been placed within the context of the cardiovascular effects as described by authors from outside our service. Papers from many other researchers are also quoted. Indeed the Introduction includes are a concise literature review of this area.
Paragraph 2.
The methods section states specifically that missing data were case wise deleted. This comment now appears in green. A line has been added to the results section stating that there were no missing data for the major dependent variables of interest. Table 3 and Supplementary Figures 1 and 2 have all been deleted as this reviewer suggests. All remarks to the sex differential in the present work have therefore been removed. This applies to the Abstract, Results and Discussion and Conclusion.
This limitation has also been specifically mentioned in the added paragraph in the limitation section of the discussion, and the conclusion has also been amended as indicated by the reviewer. The reviewer has requested that the abbreviations be replaced by plain English text. Whilst I can certainly understand this request, the complexity of the concepts and dependent variables employed by this technique make this, whilst perhaps desirable, in practice well nigh impossible.
Paragraph 3.
The reviewer is invited to revisit the Ethics paragraph. Its comments are very clear. It states:
"After appropriate consultation and advice patients gave informed consent to the study Pulse Wave Analysis (PWA) procedures."
And further:
"All patients were carefully and fully advised of the risks and benefits of the naltrexone implant insertion and gave formal written consent prior to this procedure."
Thus patients were consented verbally for the PWA procedure and in writing for the naltrexone implant insertion.
This list of confounding co-variates for which adjustment was undertaken has been shown in green for this reviewer's benefit.
